Evidence map›Paper›PMID 26053624›Full record

ArticleNature medicine2015

Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors.

Dario R Lemos, Farshad Babaeijandaghi, Marcela Low, Chih-Kai Chang, Sunny T Lee, Daniela Fiore, Regan-Heng Zhang, Anuradha Natarajan, Sergei A Nedospasov, Fabio M V Rossi

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 472 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
472citing papers in PubMed, 1 pooled it
24.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

472 citing papers in PubMed, 1 synthesis or guideline pooled it, 697 citations in OpenAlex.

  1. Skeletal muscle alterations in Marfan syndrome: a systematic review.Journal of muscle research and cell motility · 2025
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

412 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Dario R Lemos1] Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia, Canada. [2] Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Farshad Babaeijandaghi1] Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia, Canada. [2] Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Marcela Low1] Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia, Canada. [2] Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Chih-Kai Chang1] Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia, Canada. [2] Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Sunny T LeeBiomedical Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.
Daniela FioreDepartment of Experimental Medicine, Section of Medical Pathophysiology Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy.
Regan-Heng Zhang1] Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia, Canada. [2] Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Anuradha Natarajan1] Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia, Canada. [2] Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Sergei A Nedospasov1] Engelhardt Institute of Molecular Biology, Moscow, Russia. [2] Lomonosov Moscow State University, Moscow, Russia. [3] German Rheumatism Research Center, Berlin, Germany.
Fabio M V Rossi1] Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia, Canada. [2] Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000000203682620
University of British Columbia · CAEngelhardt Institute of Molecular Biology · RUSapienza University of Rome · IT

Funding

Canadian Institutes of Health Research MOP 97856
6 · The paper itself

Abstract

Depending on the inflammatory milieu, injury can result either in a tissue's complete regeneration or in its degeneration and fibrosis, the latter of which could potentially lead to permanent organ failure. Yet how inflammatory cells regulate matrix-producing cells involved in the reparative process is unknown. Here we show that in acutely damaged skeletal muscle, sequential interactions between multipotent mesenchymal progenitors and infiltrating inflammatory cells determine the outcome of the reparative process. We found that infiltrating inflammatory macrophages, through their expression of tumor necrosis factor (TNF), directly induce apoptosis of fibro/adipogenic progenitors (FAPs). In states of chronic damage, however, such as those in mdx mice, macrophages express high levels of transforming growth factor β1 (TGF-β1), which prevents the apoptosis of FAPs and induces their differentiation into matrix-producing cells. Treatment with nilotinib, a kinase inhibitor with proposed anti-fibrotic activity, can block the effect of TGF-β1 and reduce muscle fibrosis in mdx mice. Our findings reveal an unexpected anti-fibrotic role of TNF and suggest that disruption of the precisely timed progression from a TNF-rich to a TGF-β-rich environment favors fibrotic degeneration of the muscle during chronic injury.

Indexed as

AdipogenesisAnimalsApoptosisCell CountCell SurvivalChronic DiseaseCollagenElapid VenomsFemaleFibrosisFlow CytometryMacrophagesMaleMice, Inbred C57BLMice, Inbred mdxMonocytesCcr2 protein, mouseCollagenElapid VenomsnilotinibnotexinPyrimidinesReceptors, CCR2RNA, MessengerTransforming Growth Factor beta1Tumor Necrosis Factor-alpha

Identifiers

PMID26053624
OpenAlexW1574278422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.